Mavupharma
Kirkland
About Mavupharma
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $20.0M
- Funding stage: M&A
- Last round: Series A (Nov 2017)
- Website: mavupharma.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Canonical: https://fsome.com/organization/mavupharma-166362 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.